Several studies have reported the synergistic cytostatic effect of PARP inhibitors and platinum agents [27,28,29], and one study reported synergism in combined therapy comprising olaparib, carboplatin and the PI3K inhibitor buparlisib in TNBC lines but not in a HR+ breast-cancer line [32]. Here, PARP1 is linked to breast cancer.